Bertil Lindmark Biography and Net Worth

Insider of Damora Therapeutics, Inc. Common Stock

Bertil Lindmark has had an extensive and successful career in the pharmaceutical industry, building up broad clinical development and regulatory experience globally, and significant expertise in research and development in both large and small pharmaceutical organizations. As Global VP Clinical Development for the Respiratory and Inflammation franchises at AstraZeneca, Bertil led development of Symbicort, one of the worlds’ leading respiratory brands, and many other respiratory and gastro-intestinal products. From 2010, he headed Global R&D at Almirall, involving 500 staff and the successful development and approval of several new drugs in the respiratory, gastro-intestinal, neuroscience and dermatological fields. In 2015 he joined ASLAN Pharmaceuticals in Singapore with a focus on cancer and atopic skin and lung diseases. Bertil holds an MD from Lund University, Sweden with specialties in internal medicine and gastroenterology, and obtained his PhD in molecular epidemiology from Lund University. In 2019, he was appointed visiting Professor Innovation and Entrepreneurship at the Institute of Medicine at Gothenburg University, Sweden.

What is Bertil Lindmark's net worth?: The estimated net worth of Bertil Lindmark is at least $2.07 thousand as of June 28th, 2021. Lindmark owns 80 shares of Damora Therapeutics, Inc. Common Stock stock worth more than $2,066 as of April 10th. This net worth estimate does not reflect any other assets that Lindmark may own. Learn More about Bertil Lindmark's net worth.
How do I contact Bertil Lindmark?: The corporate mailing address for Lindmark and other Damora Therapeutics, Inc. Common Stock executives is GALECTO BIOTECH AB OLE MAALOES VEJ3, COPENHAGEN G7, DK-2200. Damora Therapeutics, Inc. Common Stock can also be reached via phone at 45-7070-5210 and via email at [email protected]. Learn More on Bertil Lindmark's contact information.
Has Bertil Lindmark been buying or selling shares of Damora Therapeutics, Inc. Common Stock?: Bertil Lindmark has not been actively trading shares of Damora Therapeutics, Inc. Common Stock during the past quarter. Most recently, on Tuesday, March 22nd, Bertil Lindmark bought 584 shares of Damora Therapeutics, Inc. Common Stock stock. The stock was acquired at an average cost of $54.00 per share, with a total value of $31,536.00. Learn More on Bertil Lindmark's trading history.
Who are Damora Therapeutics, Inc. Common Stock's active insiders?: Damora Therapeutics, Inc. Common Stock's insider roster includes Jonathan Freve (CFO), Bertil Lindmark (Insider), Hans Schambye (CEO), and Garrett Winslow (General Counsel). Learn More on Damora Therapeutics, Inc. Common Stock's active insiders.
Are insiders buying or selling shares of Damora Therapeutics, Inc. Common Stock?: In the last year, insiders at the sold shares 4 times. They sold a total of 1,717 shares worth more than $20,838.98. The most recent insider tranaction occured on January, 2nd when CEO Hans T Schambye sold 700 shares worth more than $14,966.00. Insiders at Damora Therapeutics, Inc. Common Stock own 10.5% of the company. Learn More about insider trades at Damora Therapeutics, Inc. Common Stock.
Information on this page was last updated on 1/2/2026.

Bertil Lindmark Insider Trading History at Damora Therapeutics, Inc. Common Stock

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
3/22/2022	Buy	584	$54.00	$31,536.00
6/28/2021	Buy	80	$131.50	$10,520.00	80

Bertil Lindmark Buying and Selling Activity at Damora Therapeutics, Inc. Common Stock

Damora Therapeutics, Inc. Common Stock Company Overview

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.

Today's Range

Now: $25.82

$25.55

$27.88

50 Day Range

MA: $26.81

$18.14

$32.30

2 Week Range

Now: $25.82

$2.14

$38.33

Volume

287,217 shs

Average Volume

276,563 shs

Market Capitalization

$1.56 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.59